DVAX Earnings

DVAX reported its earnings on 2026-02-19, showcasing a revenue of against an estimate of 77.49M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.08 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following DVAX's earnings announcement on 2026-02-19, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, DVAX's stock price tends to shift by an average of 1.36% in the 10 days leading up to earnings and 3.37% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate DVAX's annual revenue to reach 80.26M, while the EPS is projected at 0.04. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between DVAX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, DVAX's stock price typically moves by 1.36% in the 10 days before its earnings and 3.37% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.04 and revenue of 80.26M.

The earnings call highlighted strong financial performance with increased net income and adjusted EBITDA, alongside disciplined expense management. The company is optimistic about HEPLISAV-B's market share growth and strategic vaccine programs. While there are concerns about the cost of the oral COVID vaccine program, the overall sentiment in the Q&A was positive with confidence in market growth and strategic execution. The raised guidance for HEPLISAV-B and share repurchase program also contribute to a positive outlook.